Status:
COMPLETED
Symptom Management Implementation of Patient Reported Outcomes in Oncology
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
RTI International
Conditions:
Other Cancer
Gastrointestinal Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed o...
Detailed Description
A multi-disciplinary team of investigators from 6 health systems have formed the Symptom Management IMplementation of Patient Reported Outcomes in Oncology (SIMPRO) Research Center. SIMPRO will use fu...
Eligibility Criteria
Inclusion
- Stakeholder Feedback and Stakeholder Qualitative Interviews Population:
- Age ≥ 18 years
- The potential stakeholders are: patient advisory council members, health system leaders, clinicians, clinic support staff/administration, IT/Informatics staff
- Cluster Randomized Trial, Patient QualitativeInterviews, Pilot Testing \& SASS Questionnaire Population:
- Age ≥ 18 years
- Priority population will be patients who meet one of the following:
- Suspected thoracic cancer \[lung or bronchus\] AND is inpatient following thoracic surgery.
- Suspected gastrointestinal cancer \[colorectal, pancreas, liver/biliary, esophagus,or gastric\] AND is inpatient following gastrointestinal surgery.
- Suspected gynecologic cancer \[ovary, uterus, or cervix\] AND is inpatient following gynecologic surgery.
- Diagnosis of thoracic cancer \[lung or bronchus\] AND scheduled to start a new treatment plan for thoracic cancer.
- Diagnosis of gastrointestinal cancer \[colorectal, pancreas, liver/biliary, esophagus,or gastric\] AND scheduled to start a new treatment plan for gastrointestinal cancer.
- Diagnosis of gynecologic cancer \[ovary, uterus, or cervix\] AND scheduled to start a new treatment plan for gynecologic cancer.
- Total population allowed to use eSyM:
- Any patient at any participating site.
Exclusion
- \- Participants not meeting the inclusion critera above.
Key Trial Info
Start Date :
July 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 9 2025
Estimated Enrollment :
42808 Patients enrolled
Trial Details
Trial ID
NCT03850912
Start Date
July 25 2019
End Date
June 9 2025
Last Update
August 27 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Maine Medical Center
Portland, Maine, United States, 04101
2
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
3
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
4
Brown University Health (formerly Lifespan Cancer Institute)
Providence, Rhode Island, United States, 02905